financetom
Business
financetom
/
Business
/
Why Is Taysha Gene Therapies Stock Falling Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Taysha Gene Therapies Stock Falling Friday?
Oct 17, 2025 9:59 AM

Taysha Gene Therapies, Inc ( TSHA ). stock is trading lower on Friday, with a session volume of 4.695 million, as per data from Benzinga Pro.

On Thursday, during after-hours trading, the company said it regained full rights to its lead TSHA-102 program in clinical evaluation for Rett syndrome.

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), essential for regulating brain neuronal and synaptic function.

The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities, and shortened life expectancy.

The 2022 Option Agreement between Astellas Pharma, Inc ( ALPMF ) (OTC:ALPMY) and Taysha, which had granted Astellas the exclusive option to enter a negotiation period to obtain an exclusive license to TSHA-102 in Rett syndrome and certain rights with respect to change in control transactions involving Taysha, has expired.

Taysha delivered a TSHA-102 data package to Astellas in mid-2025 that contained the previously disclosed Part A REVEAL Phase 1/2 adolescent/adult and pediatric trials clinical data (May 2025 data cutoff).

100% of pediatric, adolescent, and adult patients gained ≥ one defined developmental milestone across the core functional domains of fine motor, gross motor, and communication post-TSHA-102, with a ~0% likelihood of being achieved without treatment based on natural history data.

Taysha has finalized FDA alignment on the REVEAL pivotal trial protocol and statistical analysis plan, which includes a 6-month interim analysis that may serve as the basis for BLA submission.

Price Action: TSHA stock was trading lower by 11.42% to $4.500 at last check Friday. ALPMF was down 8.81%.

Read Next:

Nio Shrugs Off Old Lawsuit, Says Operations Remain Unaffected

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved